Search research articles
Contact Us
Filters
Showing results (401-410 of 440) with videos related to
Page
of 44
Sort By:
Transplantation and Cellular Therapy
|
March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Binod Dhakal, Nina Shah, Ankit Kansagra, et al.
Cancer Cell
|
November 17, 2012
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth
Taro Hitosugi, Lu Zhou, Shannon Elf, et al.
Blood Cancer Discovery
|
June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Faith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.
Molecular Cell
|
July 7, 2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Hee-Bum Kang, Jun Fan, Ruiting Lin, et al.
American Journal of Hematology
|
September 25, 2020
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH
Robert Cornell, Parameswaran Hari, Shijie Tang, et al.
Molecular Cell
|
July 22, 2014
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth
Changliang Shan, Shannon Elf, Quanjiang Ji, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 4, 2015
New cancers after autotransplantations for multiple myeloma
Anuj Mahindra, Girindra Raval, Paulette Mehta, et al.
The Lancet. Oncology
|
December 3, 2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, et al.
The Lancet. Oncology
|
June 5, 2019
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Jens Hillengass, Saad Usmani, S Vincent Rajkumar, et al.
The Lancet. Oncology
|
December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C Lee, Ashraf Badros, et al.
Page
of 44
Search research articles
Search
Showing results (401-410 of 440) with videos related to
Sort By:
Page
of 44
Transplantation and Cellular Therapy
|
March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Binod Dhakal, Nina Shah, Ankit Kansagra, et al.
Cancer Cell
|
November 17, 2012
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth
Taro Hitosugi, Lu Zhou, Shannon Elf, et al.
Blood Cancer Discovery
|
June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Faith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.
Molecular Cell
|
July 7, 2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Hee-Bum Kang, Jun Fan, Ruiting Lin, et al.
American Journal of Hematology
|
September 25, 2020
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH
Robert Cornell, Parameswaran Hari, Shijie Tang, et al.
Molecular Cell
|
July 22, 2014
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth
Changliang Shan, Shannon Elf, Quanjiang Ji, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 4, 2015
New cancers after autotransplantations for multiple myeloma
Anuj Mahindra, Girindra Raval, Paulette Mehta, et al.
The Lancet. Oncology
|
December 3, 2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, et al.
The Lancet. Oncology
|
June 5, 2019
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Jens Hillengass, Saad Usmani, S Vincent Rajkumar, et al.
The Lancet. Oncology
|
December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C Lee, Ashraf Badros, et al.
Page
of 44